Guardant Health, Inc. last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $361.0 million (+36.1% year over year) and diluted EPS of -$0.93. It usually reports 12–37 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–37 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
361
+36.1%
|
-124
-34.1%
|
-0.93
-25.7%
|
|
Jul 30, 2026
30 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
335
+44.3%
|
-120
-20.3%
|
-0.90
-12.5%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
302
+48.3%
|
-112
-17.8%
|
-0.85
-10.4%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
281
+39.4%
|
-128
-15.8%
|
-1.00
-11.4%
|
|
Oct 29, 2025
29 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
265
+38.5%
|
-93
+13.9%
|
-0.74
+15.9%
|
|
Jul 30, 2025
30 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
232
+30.9%
|
-100
+2.7%
|
-0.80
+4.8%
|
|
Apr 30, 2025
30 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
203
+20.8%
|
-95
+17.2%
|
-0.77
+18.1%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
202
+30.2%
|
-111
+40.7%
|
-0.90
+43.2%
|
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- GH (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Palo Alto, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1576280
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
- CareDx, Inc. CDNA
Source: SEC EDGAR filings. This is company-reported data, not investment advice.